AbbVie's latest marketcap:
As of 06/17/2025, AbbVie's market capitalization has reached $337.14 B. According to our data, AbbVie is the 27th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 337.14 B |
| Revenue (ttm) | 57.37 B |
| Net Income (ttm) | 4.16 B |
| Shares Out | 1.77 B |
| EPS (ttm) | 2.34 |
| Forward PE | 16.98 |
| Ex-Dividend Date | 04/15/2025 |
| Earnings Date | 07/24/2025 |
AbbVie's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/17/2025 | $337.14 B | 7.48% | 27 |
| 12/31/2024 | $314.02 B | 14.77% | 30 |
| 12/29/2023 | $273.61 B | -4.27% | 33 |
| 12/30/2022 | $285.8 B | 19.4% | 29 |
| 12/31/2021 | $239.37 B | 26.54% | 48 |
| 12/31/2020 | $189.17 B | 44.48% | 52 |
| 12/31/2019 | $130.93 B | -5.58% | 67 |
| 12/31/2018 | $138.67 B | -10.18% | 48 |
| 12/29/2017 | $154.39 B | 51.71% | 49 |
| 12/30/2016 | $101.76 B | 5.08% | 62 |
Company Profile
About AbbVie Inc.
AbbVie Inc. is a leading research-based biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of innovative medicines and therapies worldwide. Founded in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing complex health challenges across multiple therapeutic areas.
Key Product Offerings
- Immunology: Humira (autoimmune diseases), Skyrizi (psoriasis), Rinvoq (inflammatory diseases)
- Oncology: Imbruvica (blood cancers), Venclexta/Venclyxto (blood cancers), Elahere (various cancers), Epkinly (lymphoma)
- Neuroscience: Botox Therapeutic (neurologic diseases), Vraylar (schizophrenia, bipolar disorder), Ubrelvy (migraine), Qulipta (migraine)
- Eye Care: Ozurdex (eye diseases), Lumigan/Ganfort, Alphagan/Combigan (glaucoma), Restasis (tear production)
- Gastroenterology: Mavyret/Maviret (hepatitis C), Creon (pancreatic enzyme therapy), Linzess/Constella (IBS with constipation)
Additional Therapeutic Solutions
AbbVie also provides a range of products in aesthetics, including facial injectables, regenerative medicine, body contouring, and skincare. The company continues to expand its portfolio through cutting-edge research and strategic collaborations.
Frequently Asked Questions
-
What is AbbVie's (ABBV) current market cap?As of 06/17/2025, AbbVie (including the parent company, if applicable) has an estimated market capitalization of $337.14 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does AbbVie (ABBV) rank globally by market cap?AbbVie global market capitalization ranking is approximately 27 as of 06/17/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.